ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

Is Interactive Virtual Reality Poised to Deliver a ‘Eureka Moment’ for Cardiology?

In this magazine’s cover story, we examine the work that still needs to be done to improve women’s heart health. Despite significant progress, too many women aren’t even aware that heart disease is relevant to them, let alone their gender’s leading cause of death.

Cardiovascular Business asked healthcare administrators for their favorite book recommendations. Here are a few of their responses.

Smart technologies are often touted as the answer to some of cardiology’s greatest challenges. But where does hyperbole end and reality begin?

 Enterprise Imaging for Cardiology is a unified, care-centered and sophisticated imaging platform for cardiovascular professionals.

One heartbeat scans with the industry’s fastest rotation speed in a system that is affordable and accessible in the hospital, chest pain emergency (ED), or point-of-care setting.

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.